Artificial Intelligence
Adagene Announces Updates to its Board of Directors
<!– Name:DistributionId Value:8827950 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:4573 –> <!– Name:CustomerId Value:1216234 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:2f684bfe-266e-48eb-9647-fd780e03a71d –>
SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:
- Mervyn Turner, Ph.D., is appointed as a director. Dr. Turner accumulated over 25 years of experience at Merck Research Laboratories in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years, he was head of worldwide licensing and external research at Merck, during a period of rapid expansion in Merck’s partnering activities. He became Merck’s first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011. Dr. Turner received his BS and Ph.D. in Chemistry from the University of Sheffield in 1970. He also completed his postdoctoral research in biochemistry of histocompatibility at Havard University in 1974.
- Fangyong (Felix) Du, Ph.D., is appointed as a director. Dr. Du joined Adagene as Vice President of Technology Development in January 2012 and has served as Chief Technology Officer since May 2019. Dr. Du has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr. Du worked at Affomix from October 2009 to July 2010 and Illumina from July 2010 to January 2012, and then joined the Company in January 2012 as the Vice President of Technology Development. Dr. Du received his Ph.D. degree in biology from the California Institute of Technology in 2001 and his bachelor’s degree and master’s degree in physiology and biophysics in 1991 and 1994, respectively, from Peking University. Dr. Du also completed his postdoctoral research from Yale University.
- Yumeng Wang, replaces Lefei Sun as a director immediately prior to filing of the annual report of the Company for the year of 2022 (the “Annual Report”), as designated by General Atlantic Singapore AI Pte. Ltd. pursuant to Adagene’s current effective memorandum and articles of association. Ms. Wang is a vice president at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. Prior to joining General Atlantic, Ms. Wang served as an equity research analyst at The Hongkong and Shanghai Banking Corporation, mainly focusing on the healthcare sector. Ms. Wang also serves as a non-executive director of Ocumension Therapeutics (1477.HK) and Biotheus Inc. Ms. Wang received her bachelor’s degree in business administration in June 2013 and her master’s degree in biotechnology in 2021 from The Hong Kong University of Science and Technology.
- As a result of Yumeng Wang’s replacement of Lefei Sun, he has resigned from the Board. Additionally, Yuwen Liu has resigned from the Board and audit committee of the Board effective upon filing of the Annual Report, due to expiration of her initial appointment as a director and an audit committee member. Adagene appreciates the service of Ms. Liu and her contributions to the Board.
- Each of Lefei Sun and Yuwen Liu has confirmed that there is no disagreement with the Board and there is no matter relating to his or her resignation that needs to be brought to the attention of the shareholders of the Company.
“We are excited to welcome Drs. Turner and Du and Ms. Wang to our Board, as we work to advance our differentiated clinical products rapidly to reach critical value inflection points, harvest value from our preclinical assets, and fully leverage our platform technologies to drive future growth,” said Peter Luo, Ph.D., Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene. “I am also appreciative of Lefei Sun’s many contributions during his past four years of service and the contributions of Yuwen Liu in the past year. I look forward to working with the new directors who bring a breadth of industry experience and new insights to our Board.”
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Artificial Intelligence
University medical centers in Germany choose Sectra’s radiology solution to streamline workflows and shorten lead times for patients
LINKÖPING, Sweden, April 23, 2024 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany—Universitätsklinikum Tübingen and Universitätsmedizin Göttingen. By implementing Sectra’s radiology solution, the hospitals aim to improve and streamline radiology workflows with Sectra’s tools for enhanced reporting efficiency, in turn speeding up diagnostics.
“When choosing a vendor, we wanted one that could provide us with a stable and fast system. We also wanted one facilitating collaboration among our radiologists. That way we can streamline our radiology workflows and in turn shorten lead times for patients as well as reduce the ever increasing workload for radiologists,” says Dr. Babak Panahi, Managing Senior Physician and Head of CT and CT Intervention, Universitätsmedizin Göttingen.
Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in Germany managing 300,000 and 600,000 radiology exams a year. The two separate contracts for Sectra’s radiology solution were both signed during the third quarter of Sectra’s 2023/2024 fiscal year.
“Radiologists are under a lot of pressure as they are challenged to handle more images and more complex cases with less resources. Having a solution designed to streamline radiology workflows, facilitating reading and reporting of images, is therefore paramount. I am happy and excited to support Universitätsmedizin Göttingen and Universitätsklinikum Tübingen on their journey towards efficient radiology diagnostics,” says Guido Bötticher, Managing Director, Sectra DACH.
The radiology module is part of Sectra’s enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in ‘Best in KLAS’.
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2022/2023 fiscal year totaled SEK 2,351 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/university-medical-centers-in-germany-choose-sectra-s-radiology-solution-to-streamline-workflows-and,c3965089
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-radiology-solution,c3291783
Sectra’s radiology solution
View original content:https://www.prnewswire.co.uk/news-releases/university-medical-centers-in-germany-choose-sectras-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients-302124211.html
TAIPEI, April 23, 2024 /PRNewswire/ — TXOne Networks, a frontrunner in the realm of cyber-physical systems (CPS) security, is set to unveil its groundbreaking CPS security platform, SageOne, at the highly anticipated GISec Global from April 23rd to 25th, 2024. Attendees can find TXOne Networks showcasing SageOne at stand B99 in hall 5. This innovative platform consolidates all CPS security products onto a single, central management platform, promising streamlined operations and optimized threat detection capabilities.
SageOne, aptly named “Wise Man Number One,” serves as a comprehensive management console providing a holistic view of the CPS attack surface within operational technology (OT) environments. By enabling centralized control of TXOne’s three core product lines – Stellar for endpoint protection, Element for security inspection, and Edge for network defense – SageOne facilitates integrated OT security throughout the lifecycle of protected assets, ensuring robust threat detection and response mechanisms.
Key features of SageOne include:
CPS Attack Surface Management: Prioritizing operational security by offering clear visibility into the overall security posture of OT environments, SageOne identifies security focal points, illuminating asset information and security controls.Integrated Lifecycle Protection: Through centralized management, SageOne simplifies cybersecurity governance and fosters collaborative defense. It serves as an abstraction layer, facilitating contextualization and consolidation of data across multiple products, offering tailored, task-oriented consoles for executives, security personnel, and plant leaders.CPS Threat Detection & Response: SageOne aggregates security insights from various solutions to scout for potential risks, enabling early caution and response to both known and unknown threats.SageOne’s foundation rests upon advanced components, including Threat Intelligence, Behavior-Based AI Analytics Engines, Compliance Framework, Data Visualizer, and Ecosystem Integrator, ensuring comprehensive protection and seamless integration of different tools and technologies.
With its focus on analyzing unexpected behavior and unknown threats, SageOne enables the identification of suspicious events through cross-telemetry analysis within the OT-native XDR engine. This amalgamation of advanced technologies and user-friendly interface ensures the protection of critical infrastructures.
For rapid threat response, SageOne issues early warnings of suspicious behavior and orchestrates cross-telemetry analysis for CPS Threat Detection & Response. Integrated Lifecycle Protection ensures the security of devices and systems throughout their service life, contributing to great cost efficiency.
TXOne Networks reaffirms its commitment to CPS security and continuous advancement in OT security through SageOne. Visit TXOne Networks at the GISec Global from April 23rd to 25th, 2024, at stand B99 in hall 5.
For further updates and information, follow TXOne Networks on the blog, Twitter, and LinkedIn.
About TXOne Networks:
TXOne Networks provides OT security products ensuring reliability and security in industrial control systems and operational technology environments through the OT Zero Trust methodology. Collaborating with leading industrial manufacturers and critical infrastructure operators, TXOne Networks offers practical and business-friendly approaches to OT defense. Its network and endpoint-based products secure OT networks and mission-critical devices in real-time with high security depth.
Website: www.txone.com
Photo – https://mma.prnewswire.com/media/2389611/SageOne_header_3.jpg
View original content:https://www.prnewswire.co.uk/news-releases/new-cps-protection-platform-txone-networks-unveils-sageone-at-gisec-global-302119386.html
LONDON, April 23, 2024 /PRNewswire/ — Imparta Ltd, a global leader in performance improvement for customer-facing teams, has announced the release of i-Coach AI, the world’s first sales methodology-aware AI.
Over the past 18 months, AI has reshaped many industries and professions, with sales being no exception. Yet, generic LLMs such as ChatGPT are poor at coaching, and at selling. Even data-driven AI insights are only as good as the qualitative frameworks that underpin their observations.
i-Coach AI is the first expert Sales AI Coach that follows a proven, structured coaching process, and is fluent in all aspects of sales, account management, negotiation, customer success, commercial and business acumen, sales management and sales leadership. It is powered by Imparta’s award-winning, research-based Agile 3D methodology and complete, modular skills library.
Richard Barkey, Founder and CEO of Imparta, said “GenAI is one of the few truly transformative technologies in our lifetimes, and one that no sales organisation can ignore. We are genuinely excited to introduce i-Coach AI, an enterprise-grade coaching tool for salespeople, managers and leaders. I’m not exaggerating when I say that I’m using i-Coach AI myself, to think through strategies around specific clients, and indeed for the whole business. This tool is designed to integrate seamlessly across various sales ecosystems and tech stacks, and provides targeted, IP-aware coaching and practice simulations of customer conversations, at multiple points of need.”
As part of the launch, Imparta will host a webinar on April 23rd and May 2nd, hosted by Richard Barkey, titled ‘Leveraging Sales Methodology-Aware AI at Scale in the Enterprise’. Click here to learn more.
During this webinar, Richard will announce details of i-Coach AI and Imparta’s upcoming course for sales teams: Leveraging AI for Sales. He will also set out a range of essential use cases that we are rolling out across Imparta’s agile sales ecosystem and across the tech stack.
About Imparta
Imparta is a global leader in performance improvement for Sales, CX and Leadership. Our modular ecosystem includes three elements, developed through 25 years of research and experience with leading global organisations: Agile Sales Methodology, Agile Change Process and AI Sales Technology.
Whether you need to plug a gap in your existing training, provide self-paced learning, or build an entire Sales, CX or Leadership Academy, get in touch at [email protected].
Website: www.imparta.com
Photo: https://mma.prnewswire.com/media/2392278/i_Coach_Imparta_Ltd.jpg
Contact details: Adam [email protected] Tel: +44 (0) 20 7610 8800
View original content:https://www.prnewswire.co.uk/news-releases/imparta-launches-worlds-first-sales-methodology-aware-ai-302123771.html
-
Artificial Intelligence6 days agoHuawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Uncategorized4 days agoGenerative AI gold rush drives IT spending — with payoff in question
-
Uncategorized4 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized4 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized4 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Uncategorized4 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized4 days ago
The Ottawa Hospital doctors to try AI for patient notes
-
Artificial Intelligence7 days agoSQream’s No-Code Platform Panoply Earns 21 G2 Badges in Key Customer Satisfaction Categories for Spring 2024 Report
